Table 5.
Published literature for HCC patients received HAIC+TKIs+PD-1 treatment.
| Study (Year), Design | Treatment | Patients | BCLC stageB/C | HAIC | TKIs | PD-1/PD-L1 | CR | ORR | DCR | Conversion rate | MedianOS (months) | MedianPFS(months) | AE rate(Grade≥3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (2021), Retrospective | HAIC+TKIs+PD-1 | 25 | 0/25 | FOLFOX | Apatinib Lenvatinib Sorafenib |
Camrelizumab Sintilimab | 48% | 96% | 100% | 56% | Not reached (median follow-up 12.53) |
not reached | 28% |
| 2 (2021), Retrospective | HAIC+Lenvatinib+ Toripalimab Lenvatinib |
71 86 |
0/71 0/86 |
FOLFOX | Lenvatinib | Toripalimab | 14.1% vs 0% |
67.6% vs 14.3% |
90.1% vs 72.1% |
/ | Not reached vs 11 |
11.1 vs 5.1 |
Combination therapy group higher |
| 3 (2021), Retrospective | HAIC+PD1+Lenvatinib Lenvatinib+PD-1 |
45 25 |
5/40 3/22 |
FOLFOX | Lenvatinib | Nivolumab Keytruda Toripalimab Sintilimab |
0% vs 0% |
40.0% vs 16.0% |
77.6% vs 44.0% |
/ | 15.9 vs 8.6 |
8.8 vs 5.4 |
22.2% vs 36.0% |
| 4 (2021), Retrospective | HAIC+TKIs+PD-1 | 27 | 0/27 | FOLFOX | Lenvatinib Regorafenib Sorafenib Apatinib |
Camrelizumab Sintilimab Toripalimab Nivolumab |
22.2% | 63.0% | 92.6% | / | Not reached (median follow-up 12.9) |
12.9 | 55.6% (All grade 3) |
| 5(2021), Retrospective | HAIC+ Pembrolizumab+ Lenvatinib Lenvatinib+Pembrolizumab |
84 86 |
22/62 21/65 |
FOLFOX | Lenvatinib | Pembrolizumab | 15.5% vs 9.3% |
59.5% vs 41.9% |
89.3% vs 86.1% |
/ | 17.7 vs 12.6 |
10.9 vs 6.8 |
4.8% vs 2.3% |
| 6 Ours, Retrospective | HAIC+PD-1+TKIs | 145 | 41/104 | FOLFOX RALOX |
Sorafenib Lenvatinib Apatinib |
Camrelizumab Stintilimab Tislelizumab |
6.1% | 57.2% | 89.7% | 18.6% | not reached (median follow-up 12.5) | 9.7 | 17.7% |
1、Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy:A Retrospective Study.
2、Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus Lenvatinib alone for advanced hepatocellular carcinoma.
3、Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma.
4、Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
5、Pembrolizumab plus Lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
TKIs, tyrosine kinase inhibitors; HAIC, hepatic arterial infusion chemotherapy; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand-1FOLFOX Regiment, oxaliplatin+leucovorin+5-fluorouracil; RALOX Regiment, raltitrexed + oxaliplatin; BCLC, Barcelona Clınic Liver Cancer; CR, complete response; DCR, disease control rate; ORR, objective response rate.